A retrospective cohort study evaluating effect of acid reducing agents on efficacy of Vemurafenib in BRAF V600 mutation-positive unresectable or metastatic melanoma patients.

Next Previous
Trial Profile

A retrospective cohort study evaluating effect of acid reducing agents on efficacy of Vemurafenib in BRAF V600 mutation-positive unresectable or metastatic melanoma patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Apr 2018 Results (n=112) published in the Targeted Oncology.
    • 13 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top